IP Library Granted Patent US 8,686,006
Granted Patent B2
US 8,686,006 · App. 13/124,797 · Granted Apr 1, 2014

Pharmaceutical composition for improving intestinal absorption

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,686,006
App. No.
13/124,797
Granted
Apr 1, 2014
Kind
B2
Abstract

An object of the present invention is to provide a pharmaceutical composition that improves intestinal absorption of a compound having a structure represented by the general formula [1]. The composition containing a compound represented by the general formula [1] or a salt thereof and (b) a lipophilic substance improves intestinal absorption of the compound. In the formula, A represents —(NR 4 )—, —(CR 5 R 6 )— or the like; B represents an alkylene group or an alkenylene group; R 1 represents an alkyl group, an alkenyl group or the like; R 2 represents an adamantylalkyl group or the like; R 3 represents an unsaturated heterocyclic ring; R 4 , R 5 and R 6 each represent a hydrogen atom or the like; and X represents an oxygen atom or the like.

Claims (4)

1. A pharmaceutical composition comprising (a) 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea or a salt thereof and (b) a lipophilic substance, wherein the lipophilic substance is a propylene glycol monocaprylate.

2. The composition according to claim 1 , which further comprises a solubilizer and/or a surfactant.

3. A method for improving intestinal absorption of 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea or a salt thereof, which method comprises administering to a patient a pharmaceutical composition comprising (a) 1-[2-(1-adamantyl)ethyl]-1-pentyl-3-[3-(4-pyridyl)propyl]urea and (b) a lipophilic substance, wherein the lipophilic substance is propylene glycol monocaprylate.

4. The method according to claim 3 , wherein the pharmaceutical composition comprises a solubilizer and/or a surfactant.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NUMBER 7122598 PREVIOUSLY RECORDED ON REEL 037834 FRAME 0513. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD BE 7112598. Recorded Apr 12, 2016
From: SANTEN PHARMACEUTICAL CO.,LTD.
To: AYUMI PHARMACEUTICAL CORPORATION
Reel/Frame 038408/0987 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2016
From: SANTEN PHARMACEUTICAL CO.,LTD.
To: AYUMI PHARMACEUTICAL CORPORATION
Reel/Frame 037834/0513 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2011
From: UMEDA, MASAYUKI; KIMURA, AKIO; UEDA, KENJI; SAKANAKA, KOJI
To: SANTEN PHARMACEUTICAL CO., LTD.
Reel/Frame 026144/0511 →